

The Financial Express, Delhi

Thursday, 25th November 2010, Page: 4

Width: 6.14 cms Height: 6.94 cms, Ref: pmin.2010-11-25.32.22

Delhi HC nullifies NPPA order on Ranbaxy Labs

In a favourable development for Ranbaxy Labs, the Delhi High Court has nullified a National Pharmaceuticals Pricing Authority order which had dismissed the review petitions of the Gurgaon-based drugmaker. The review petition called for reconsideration of a NPPA notification (in the light of the facts furnished by Ranbaxy) which fixed the ceiling price of the anti-infective drug Roscillin (strength 500 mg and 250 mg), mainly used in cases of urinary tract infection. Ranbaxy had contested the government's decision in the HC by arguing that the drug price regulator did not take into account the evidence that the firm presented to it in a review petition.

NPPA